Ftse Mib
34.186,18
0,07%
DAX
19.909,14
-0,25%
S&P 500
5.881,63
-0,43%
NASDAQ
19.310,79
-0,90%
Bitcoin
93.825,65
0,47%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cullinan Therapeutics Inc (CGEM) Cullinan Therapeutics Inc (CGEM) Notizie

CGEM

Cullinan Therapeutics (CGEM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CGEM
DataOraFonteTitoloSimboloCompagnia
20/12/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
14/11/202423:05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CGEMCullinan Therapeutics Inc
14/11/202416:01GlobeNewswire Inc.Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024NASDAQ:CGEMCullinan Therapeutics Inc
08/11/202420:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CGEMCullinan Therapeutics Inc
07/11/202413:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGEMCullinan Therapeutics Inc
07/11/202413:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGEMCullinan Therapeutics Inc
07/11/202413:00GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
05/11/202413:00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare ConferenceNASDAQ:CGEMCullinan Therapeutics Inc
04/11/202413:00GlobeNewswire Inc.Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/10/202413:00GlobeNewswire Inc.Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
17/09/202413:00GlobeNewswire Inc.Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
16/09/202413:00GlobeNewswire Inc.Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus ErythematosusNASDAQ:CGEMCullinan Therapeutics Inc
14/09/202410:15GlobeNewswire Inc.Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024NASDAQ:CGEMCullinan Therapeutics Inc
05/09/202422:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGEMCullinan Therapeutics Inc
28/08/202414:00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CGEMCullinan Therapeutics Inc
08/08/202413:00GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
05/06/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGEMCullinan Therapeutics Inc
04/06/202423:06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CGEMCullinan Therapeutics Inc
01/06/202413:00GlobeNewswire Inc.Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of ZipalertinibNASDAQ:CGEMCullinan Therapeutics Inc
24/05/202414:00GlobeNewswire Inc.Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitNASDAQ:CGEMCullinan Therapeutics Inc
23/05/202423:04GlobeNewswire Inc.Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/05/202422:10Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CGEMCullinan Therapeutics Inc
16/05/202413:30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202412:42Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CGEMCullinan Therapeutics Inc
16/05/202412:40Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CGEMCullinan Therapeutics Inc
15/05/202422:05GlobeNewswire Inc.Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:CGEMCullinan Therapeutics Inc
29/04/202413:00GlobeNewswire Inc.Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerNASDAQ:CGEMCullinan Therapeutics Inc
24/04/202416:09GlobeNewswire Inc.Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024NASDAQ:CGEMCullinan Therapeutics Inc
16/04/202413:00GlobeNewswire Inc.Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesNASDAQ:CGEMCullinan Therapeutics Inc
16/04/202412:59GlobeNewswire Inc.Cullinan Therapeutics Announces Oversubscribed $280 million Private PlacementNASDAQ:CGEMCullinan Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CGEM

La tua Cronologia

BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STMMI
ST Microelectronics
BIT
TIT
Telecom Italia
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
TEN
Tenaris
BIT
CPR
Davide Campari
BIT
MONC
Moncler
BIT
SPM
Saipem
BIT
LDO
Leonardo
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network